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In a nested case-control study of 513 women with cancer; 130 with cardiovascular disease and equal numbers of controls, we
found no effect of randomised beta-carotene on risk of cancer or cardiovascular disease within any quartile of baseline plasma
beta-carotene, nor was there a trend across quartiles (P for trend 0.15 and 0.62, respectively).
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Observational epidemiologic studies have consistently indicated
that individuals who consume large amounts of fruits and vegeta-
bles rich in b-carotene experience lower cancer rates (e.g., Van
Poppel, 1996; Toniolo et al, 2001). However, randomised trials
testing b-carotene supplementation, alone or in combination with
other supplements, have not supported this (Greenberg et al, 1990;
Blot et al, 1993; Li et al, 1993; The Alpha-Tocopherol, Beta Caro-
tene Cancer Prevention Study Group, 1994; Hennekens et al, 1996;
Omenn et al, 1996b; Lee et al, 1999). Of seven trials, one observed
a signiﬁcant beneﬁt on cancer mortality (Blot et al, 1993), four
reported no signiﬁcant beneﬁt or harm on the incidence of cancer
and cardiovascular disease (Greenberg et al, 1990; Li et al, 1993;
Hennekens et al, 1996; Lee et al, 1999), while the remaining two
trials found an unexpected, but signiﬁcant increase in lung cancer
incidence (Omenn et al, 1996b; The Alpha-Tocopherol, Beta Caro-
tene Cancer Prevention Study Group, 1994). The only trial
reporting a beneﬁt of b-carotene supplementation tested a combi-
nation of beta-carotene, vitamin E, and selenium among poorly
nourished adults in China (Blot et al, 1993). This has raised the
hypothesis that any beneﬁt of b-carotene supplementation may
be limited to those with low levels of plasma b-carotene. In this
paper, we conduct a post-hoc analysis to test the hypothesis using
data from the Women’s Health Study (WHS), where we previously
observed no overall beneﬁt or harm from b-carotene on cancer and
cardiovascular disease (Lee et al, 1999).
MATERIALS AND METHODS
The WHS was originally designed as a randomised, double-blind,
placebo-controlled trial testing the balance of beneﬁts and risks
of aspirin (Bayer AG, Leverkusen, Germany), vitamin E (Natural
Source Vitamin E Association, Washington, DC, USA), and b-
carotene (Lurotin, 50 mg every other day; BASF Corporation,
Wyandotte, MI, USA) in the primary prevention of cancer and
cardiovascular disease among 39876 female health professionals
aged 545 years (Buring and Hennekens, 1992a,b; Rexrode et al,
2000). Written informed consent was obtained from the women,
and the trial was approved by the institutional review board of
Brigham and Women’s Hospital (Boston, MA, USA). The b-caro-
tene component of the trial was terminated early on January 18,
1996 after a median treatment duration of 2.1 years, based on
the null ﬁndings in the Physicians’ Health Study (Hennekens et
al, 1996) and also because two other trials had suggested increased
risk of lung cancer (The Alpha-Tocopherol, Beta Carotene Cancer
Prevention Study Group, 1994; Omenn et al, 1996b). (The aspirin
and vitamin E components are currently ongoing.)
Prior to randomisation, women were asked to provide baseline
blood samples; 28133 (71%) did so. Plasma samples were stored
at 71708C. The occurrence of cancer and cardiovascular disease
was ascertained using questionnaires sent twice in the ﬁrst year
and yearly thereafter. Deaths were reported by family members
or postal authorities. We obtained medical records to conﬁrm
the occurrence of cancer and cardiovascular events. After a
median follow-up of 4.1 years, 747 conﬁrmed cases of cancer
and 218 of cardiovascular disease (non-fatal myocardial infarction,
non-fatal stroke, or cardiovascular death) had occurred. Of these
women with cancer and cardiovascular disease, 513 and 130,
respectively, had provided baseline blood samples; they represent
the cases for the present nested case–control study. For each case,
we selected a control subject who had provided a baseline blood
sample and had no cancer or cardiovascular disease up to the
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(within 1 year), smoking habit, and time since randomisation
(within 6 months).
We measured plasma b-carotene by high performance liquid
chromatography using Shimadzu system (De Leenheer et al,
1979). This assay was standardised using calibrators from the
National Institute of Standards and Technology. The intra- and
inter-assay coefﬁcients of variation were 54.2% and 56.1%,
respectively. Plasma samples from each case and matching control
were assayed in random order within the same batch to minimise
inter-assay variability, and laboratory personnel were blinded to the
case or control status of samples.
We compared the baseline characteristics of cases and controls
using stratiﬁed analysis of matched sets. Proportions were
compared with the stratiﬁed Cochran–Mantel Haenszel test;
means, with models allowing for the correlation of values within
matched sets, using PROC MIXED of SAS (SAS Institute Inc,
1997). We then categorised women into quartiles of plasma b-caro-
tene at baseline. Conditional logistic regression analysis was
performed using Cox proportional hazards models stratiﬁed by
matched set (Breslow and Day, 1980). Models were additionally
adjusted for randomised aspirin and vitamin E. To evaluate the
joint association of baseline b-carotene and randomised b-caro-
tene, models were ﬁt with interaction terms between quartile of
baseline plasma b-carotene level and randomised b-carotene
assignment.
RESULTS
The baseline characteristics of cancer cases and their matched
controls are shown in Table 1. The mean age was 56.7 years. Just
over 15% of women were smoking cigarettes at baseline. Cancer
cases and controls did not differ signiﬁcantly in body mass index,
alcohol intake, physical activity, menopausal status, or use of post-
menopausal hormones. At baseline, they had very similar plasma
levels of b-carotene (13.6 and 13.7 mgd l
71, respectively) and diet-
ary intake of b-carotene (4146 and 4150 mg day
71). Similar
proportions were randomised to active b-carotene (51.9 and
48.0%).
Women with cardiovascular disease and their matched controls
were older at baseline, with a mean age over 60 years, and included
more current smokers (26.9%). Women with cardiovascular disease
were heavier than controls; drank more alcohol; and were more
likely to have a personal history of hypertension, high cholesterol,
and diabetes mellitus, and a parental history of early myocardial
infarction. However, they did not differ in physical activity, post-
menopausal status, or use of postmenopausal hormones. They
also did not differ signiﬁcantly in baseline levels of plasma b-caro-
tene (13.5 and 14.8 g dl
71, respectively), dietary intake of b-
carotene (3996 and 4156 mg day
71), and proportion randomised
to active b-carotene (51.5 and 46.2%).
Table 2 shows the results from conditional logistic regression
analysis of the associations of both plasma b-carotene level at base-
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Table 1 Baseline characteristics among matched sets from a nested case–control comparison within the Women’s Health
Study
Cancer Cardiovascular disease
Cases Controls Cases Controls
(n=513) (n=513) P (n=130) (n=130) P
Mean age, years (s.d.) 56.6 (7.7) 56.7 (7.7) Matched 60.4 (8.6) 60.3 (8.5) Matched
Mean body mass index (kg m
2) (s.d.) 25.9 (4.8) 25.8 (4.8) 0.83 27.6 (5.4) 25.7 (4.7) 0.003
Cigarette smoking (%) Matched Matched
Never smoked 45.4 45.4 41.5 41.5
Past smoker 39.4 39.4 31.5 31.5
Current smoker 15.2 15.2 26.9 26.9
Alcohol consumption (%) 0.11 0.04
Rarely 40.9 44.4 43.1 54.6
1–3 drinks per month 11.1 14.4 16.9 12.3
1–6 drinks per week 35.7 29.6 26.2 28.5
51 drink per day 12.3 11.5 13.9 4.6
Physical activity (%) 0.83 0.28
5200 kcal week 25.3 25.8 39.1 29.9
200–599 kcal per week 24.7 25.6 21.1 24.4
600–1499 kcal per week 28.1 26.0 26.6 33.1
51500 kcal per week 21.9 22.5 13.3 12.6
Per cent postmenopausal 68.0 64.7 0.26 81.4 75.4 0.24
Postmenopausal hormone use
a (%) 0.57 0.25
Never 32.0 33.1 29.5 40.8
Past 16.1 9.9 26.7 18.4
Current 51.9 56.9 43.8 40.8
Per cent with hypertension 27.3 25.0 0.40 56.9 34.9 0.001
Per cent with high cholesterol 33.7 32.9 0.79 47.7 32.3 0.01
Per cent with diabetes mellitus 2.9 2.5 0.71 10.8 3.1 0.02
Parental history of myocardial infarction
560 years (%) 12.4 14.9 0.25 22.7 10.7 0.01
Plasma b-carotene (mgd l
71) (s.d.)
b 13.6 (14.2) 13.7 (14.5) 0.93 13.5 (12.4) 14.8 (15.2) 0.33
Dietary b-carotene (mg day
71) (s.d.)
b 4146 (2967) 4150 (2684) 0.97 3996 (3976) 4156 (2803) 0.65
Randomized b-carotene assignment (%) 51.9 48.0 0.21 51.5 46.2 0.39
aAmong postmenopausal women.
bGeometric mean; test is based on the natural logarithmic transformation.
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ovascular disease. For cancer, there was no evidence that higher
plasma levels were related to decreased risk (odds ratio (OR)
comparing highest vs lowest quartile among women assigned place-
bo b-carotene=0.98; 95% conﬁdence interval (CI)=0.60–1.60), and
the trend in risk across quartiles was nonsigniﬁcant (P,
trend=0.96). We next examined the effect of randomised b-caro-
tene supplementation, within quartiles of baseline plasma b-
carotene levels. There was no effect of randomised b-carotene in
any quartile, nor was there a trend across quartiles (P, trend=0.15).
Additional adjustment for body mass index, alcohol intake, physi-
cal activity, menopausal status, and use of postmenopausal
hormones did not change these ﬁndings (data not shown).
For cardiovascular disease, a higher plasma level of b-carotene at
baseline also was not predictive of lower risk (corresponding
OR=0.85; 95% CI=0.29–2.48; P, trend=0.90). As with cancer, there
was no effect of randomised b-carotene in any quartile (P,
trend=0.62). Additional adjustment for the potential confounders
above, plus personal history of hypertension, high cholesterol,
and diabetes mellitus, and a parental history of early myocardial
infarction did not change our conclusions (data not shown).
DISCUSSION
Previous analyses of all 39876 women in the WHS revealed no
overall beneﬁt or harm of randomised b-carotene supplementation
on cancer or cardiovascular disease, after a median treatment dura-
tion of 2.1 years and a median follow-up of 4.1 years (Lee et al,
1999). In the present case–control study nested within the WHS,
the data further show that no effect is observed, regardless of base-
line plasma b-carotene level.
In concert with these ﬁndings, the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention (ATBC) Study reported no effect of
baseline serum b-carotene on the association between randomised
b-carotene supplementation and lung cancer risk (Albanes et al,
1996). Likewise, the Beta-Carotene and Retinol Efﬁcacy Trial
(CARET) observed the same relative risk for lung cancer among
those assigned a combination of b-carotene and retinyl palmitate
supplements vs placebo, regardless of whether baseline serum b-
carotene was below or above the median (Omenn et al, 1996a).
In contrast, the Physicians’ Health Study (PHS) reported that the
effect of randomised b-carotene on cancer risk was marginally
different (P, trend=0.09) across quartiles of baseline plasma b-caro-
tene levels, with the largest beneﬁt seen in the lowest quartile
(Cook et al, 1999). This trend was primarily due to a beneﬁt for
prostate cancer risk, which may explain the different ﬁnding from
the WHS.
The present ﬁndings do not necessarily refute the hypothesis
that b-carotene supplementation may be beneﬁcial to those with
low levels of plasma b-carotene. In the Chinese study where
decreased cancer mortality was observed among individuals
randomly assigned a combination of b-carotene, vitamin E and
selenium, the mean baseline blood level of b-carotene was 5.9–
6.8 mgd l
71 (Blot et al, 1993). This was higher in the WHS
(13.7–14.8 mgd l
71), as well as in the three other trials conducted
among well-nourished populations (ATBC study: median,
17 mgd l
71; 20th–80th percentile, 10–29 mgd l
71 (The Alpha-
Tocopherol, Beta Carotene Cancer Prevention Study Group,
1994); CARET: median, 15.2 mgd l
71 (Omenn et al, 1996a);
PHS: mean among men free of cancer, 22.5 mgd l
71; 25th–75th
percentile, 15.3–34.4 mgd l
71 (Cook et al, 1999)). Therefore, the
difference in ﬁndings among these trials may reﬂect the different
nutritional status of the subjects.
Strengths of the present study include good compliance with
randomised treatment assignment (Lee et al, 1999) and careful docu-
mentation of endpoints. A major limitation, however, is that
randomised treatment with b-carotene lasted only 2.1 years before
early termination, so we could not evaluate long-term treatment.
Follow-up duration was also limited; the relatively few cases of cardi-
ovascular disease led to ﬁndings with wide conﬁdence intervals.
Another concern is that only 71% of WHS women provided blood
samples at baseline and analyses were limited to women with a base-
line blood sample. However, adjustment for multiple risk factors for
cancer and cardiovascular disease, which might be related to baseline
blood contribution, did not change the results.
In conclusion, these data do not suggest that b-carotene supple-
mentation is beneﬁcial to individuals with the lowest plasma levels
of b-carotene as found within this study. However, because
subjects were adequately nourished, we could not examine this
question among those with levels of b-carotene that might be seen
in a malnourished population. Further, treatment duration was
short, precluding the evaluation of long-term supplementation.
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Table 2 Association of baseline plasma b-carotene and randomized b-carotene assignment within quartile of
baseline plasma b-carotene with cancer and cardiovascular disease from a nested case–control comparison
within the Women’s Health Study
Effect of baseline plasma
b-carotene
Effect of randomised
b-carotene, within
quartile of baseline
plasma b-carotene
Baseline plasma b-carotene
a Cases Controls OR
b 95% CI P OR 95% CI P
Cancer
Q1 (lowest) 137 134 1.00 Referent – 1.30 0.81–2.09 0.28
Q2 109 127 1.00 0.61–1.64 1.00 0.85 0.52–1.40 0.52
Q3 137 127 1.02 0.64–1.64 0.94 1.36 0.83–2.23 0.22
Q4 (highest) 130 125 0.98 0.60–1.60 0.93 1.34 0.81–2.22 0.26
Trend 0.96 0.15
Cardiovascular disease
Q1 (lowest) 31 26 1.00 Referent – 2.34 0.76–7.19 0.14
Q2 30 34 1.08 0.37–3.18 0.88 0.97 0.36–2.61 0.95
Q3 40 33 1.76 0.63–4.95 0.28 0.87 0.35–2.18 0.77
Q4 (highest) 29 37 0.85 0.29–2.48 0.77 1.49 0.54–4.06 0.44
Trend 0.90 0.62
OR: odds ratio; CI: conﬁdence interval.
aQuartiles of baseline plasma b-carotene: Q1=4.99–57.01; Q2=7.01–513.19;
Q3=13.19–524.4; Q4=524.4 mgd l
71.
bEstimated odds ratio for quartiles of baseline plasma b-carotene, among those
randomised to b-carotene placebo.
b-carotene and cancer and CVD
I-M Lee et al
700
British Journal of Cancer (2002) 86(5), 698–701 ã 2002 Cancer Research UKACKNOWLEDGEMENTS
This reasearch was supported by Public Health Service grants CA-
47988 from the National Cancer Institute and HL-43851 from the
National Heart, Lung and Blood Institute, and an investigator-
initiated grant from Roche Vitamins, Inc. The authors would like
to acknowledge Dr Nadir Rifai for conducting the laboratory
assays, the crucial contributions of the entire staff of the WHS,
and the 39876 dedicated and committed participants of the WHS.
REFERENCES
Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M,
Hartman AM, Palmgren J, Freedman LS, Haapakoski J, Barrett MJ, Pieti-
nen P, Malila N, Tala E, Liippo K, Salomaa E-R, Tangrea TA, Teppo L,
Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK (1996) a-toco-
pherol and b-carotene supplements and lung cancer incidence in the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: Effects of
base-line characteristics and study compliance. J Natl Cancer Inst 88:
1560–1570
Breslow NE, Day NE (1980) Statistical Methods in Cancer Research I: The
Analysis of Case–Control Studies IARC Scientiﬁc Pub No. 32 Lyon: Inter-
national Agency for Research on Cancer
Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, Yang CS, Zheng S-
F, Gail M, Li G-Y, Yu Y, Liu B-Q, Tangrea J, Sun Y-H, Liu F, Fraumeni JF,
Zhang Y-H, Li B (1993) Nutrition intervention trials in Linxian, China:
Supplementation with speciﬁc vitamin/mineral combinations, cancer inci-
dence, and disease speciﬁc mortality in the general population. J Natl
Cancer Inst 85: 1483–1492
Buring JE, Hennekens CH (1992a) The Women’s Health Study: Summary of
the study design. J Myocard Ischemia 4: 27–29
Buring JE, Hennekens CH (1992b) The Women’s Health Study: Rationale
and background. J Myocard Ischemia 4: 30–40
Cook NR, Stampfer MJ, Ma J, Manson JE, Sacks FM, Buring JE, Hennekens
CH (1999) b-carotene supplementation for patients with low baseline
levels and decreased risks of total and prostate carcinoma. Cancer 86:
1783–1792
De Leenheer AP, Bevere VO, De Ruyter MG, Claeys AE (1979) Simultaneous
detection of retinol and alpha-tocopherol in human serum by high perfor-
mance liquid chromatography. J Chromatogr 162: 408–413
Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK,
Elias PM, Lowe N, Nierenberg DW, Bayrd G (1990) A clinical trial of beta
carotene to prevent basal-cell and squamous-cell cancers of the skin. N
Engl J Med 323: 789–795
Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR,
Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R
(1996) Lack of effect of long-term supplementation with beta carotene
on the incidence of malignant neoplasms and cardiovascular disease. N
Engl J Med 334: 1145–1149
Lee I-M, Cook NR, Manson JE, Buring JE, Hennekens CH (1999) Beta caro-
tene supplementation and incidence of cancer and cardiovascular disease:
The Women’s Health Study. J Natl Cancer Inst 91: 2102–2106
Li J, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu S-F, Yang
CS, Shen Q, Wang W, Mark SD, Zou X-N, Greenwald P, Wu Y-P, Blot WJ
(1993) Nutrition intervention trials in Linxian, China: Multiple vitamin/
mineral supplementation, cancer incidence, and disease-speciﬁc mortality
among adults with esophageal dysplasia. J Natl Cancer Inst 85: 1492–1498
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A,
Keogh JP, Meyskens Jr FL, Valanis B, William Jr JH, Barnhart S, Cherniak
MG, Brodkin CA, Hammar S (1996a) Risk factors for lung cancer and for
intervention effects in CARET, the Beta-Carotene and Retinol Efﬁcacy
Trial. J Natl Cancer Inst 88: 1550–1559
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A,
Keogh JP, Meyskens Jr FL, Valanis B, William Jr JH, Barnhart S, Hammar
S (1996b) Effects of a combination of beta carotene and vitamin A on lung
cancer and cardiovascular disease. N Engl J Med 334: 1150–1155
Rexrode KM, Lee I-M, Cook NR, Hennekens CH, Buring JE (2000) Baseline
characteristics of participants in the Women’s Health Study. J Women’s
Health 9: 19–27
SAS Institute Inc (1997) SAS/STAT Software: Changes and Enhancements
through Release 6.12 Cary, NC: SAS Institute Inc
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group
(1994) The effect of vitamin E and beta carotene on the incidence of lung
cancer and other cancers in male smokers. New Engl J Med 330: 1029–
1035
Toniolo P, Van Kappel AL, Akhmedkhanov A, Ferrari P, Kato I, Shore RE,
Riboli E (2001) Serum carotenoids and breast cancer. Am J Epidemiol
153: 1142–1147
Van Poppel G (1996) Epidemiologic evidence for b-carotene in prevention of
cancer and cardiovascular disease. Eur J Clin Nutr 50: (Suppl 3): S57–S61
E
p
i
d
e
m
i
o
l
o
g
y
b-carotene and cancer and CVD
I-M Lee et al
701
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 698–701